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CXCL12-CXCR4-CXCR7 signaling promotes tumor growth and metastasis in breast cancer. Alternative splicing of
CXCL12 produces isoforms with distinct structural and biochemical properties, but little is known about isoform-
specific differences in breast cancer subtypes and patient outcomes. We investigated global expression profiles of
the six CXCL12 isoforms, CXCR4, and CXCR7 in The Cancer Genome Atlas breast cancer cohort using next-
generation RNA sequencing in 948 breast cancer and benign samples and seven breast cancer cell lines. We
compared expression levels with several clinical parameters, as well as metastasis, recurrence, and overall survival
(OS). CXCL12-α, -β, and -γ are highly co-expressed, with low expression correlating with more aggressive
subtypes, higher stage disease, and worse clinical outcomes. CXCL12-δ did not correlate with other isoforms but
was prognostic for OS and showed the same trend for metastasis and recurrence-free survival. Effects of CXCL12-δ
remained independently prognostic when taking into account expression of CXCL12, CXCR4, and CXCR7. These
results were also reflected when comparing CXCL12-α, -β, and -γ in breast cancer cell lines. We summarized
expression of all CXCL12 isoforms in an important chemokine signaling pathway in breast cancer in a large clinical
cohort and common breast cancer cell lines, establishing differences among isoforms in multiple clinical,
pathologic, and molecular subgroups. We identified for the first time the clinical importance of a previously
unstudied isoform, CXCL12-δ.
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Nearly all human genes undergo alternative splicing, substantially
increasing diversity in protein structure and function [1]. Genome-
wide analyses of several different cancers demonstrate extensive
perturbations in splicing during tumor initiation and metastasis [2,3].
Alternatively spliced proteins regulate fundamental processes in
cancer, including apoptosis, metabolism, and metastasis, suggesting
that dysregulated splicing is critical to malignancy [4–6]. As
prominent examples of alternative splicing in cancer, a switch from
pyruvate kinase M1 to the M2 isoform drives anabolic metabolism in
malignant cells, and a novel splice variant of the transmembrane
protein CD44 promotes metastasis [5,7–9]. Isoforms of these and
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provide potential biomarkers for detection of cancer and may
contribute to drug resistance of cancer cells. Identifying changes in
protein isoform expression in cancer will improve understanding of
key signaling pathways in tumorigenesis and point to novel
therapeutic targets to improve cancer therapy [10,11].
Chemokine CXCL12 and its chemokine receptors CXCR4 and
CXCR7 (recently renamed as ACKR3) comprise a signaling axis
strongly linked to tumor growth and metastasis in breast cancer and
more than 20 other malignancies [12,13]. CXCL12 binding to CXCR4
activates pathways including phosphatidylinositol-3 kinase and mito-
gen-activated protein kinases to promote growth, survival, and
chemotaxis of breast cancer cells. High levels of CXCL12 are expressed
in common sites of breast cancer metastasis such as lung, liver, bone,
and brain [14]. CXCR4 commonly is upregulated on breast cancer cells,
and numerous studies have demonstrated both gene and protein
overexpression of CXCR4 on cancer cells in primary breast tumors [15–
18]. The anatomic distribution of CXCL12 and studies in mouse
models of cancer suggest that gradients of this chemokine drive local
invasion and subsequent homing of CXCR4+ breast cancer cells to
secondary sites [18,19]. CXCR7 also is expressed by breast cancer cells
and stromal cells, such as endothelium on tumor vasculature, in primary
breast cancers [20]. CXCR7 functions as a scavenger receptor for
CXCL12, functioning in part to decrease amounts of this chemokine in
the extracellular space and establish chemotactic gradients [21,22].
CXCR7 also promotes survival and invasion of malignant cells [23].
Although six different isoforms of human CXCL12 (α, β, γ, δ, ε,
and φ) have been described, most studies of CXCL12 focus only on
the α isoform or do not distinguish among isoforms [24]. CXCL12
may be secreted by malignant cells in primary breast cancers in
addition to carcinoma-associated fibroblasts and/or mesenchymal
stem cells in the tumor microenvironment [17,25,26]. Fibroblasts
isolated from primary breast tumors secrete CXCL12 at higher levels
than fibroblasts from normal mammary tissue despite no genetic
mutations in stroma [27,28]. These findings suggest that cancer cells
stimulate adjacent fibroblasts to produce higher levels of total
CXCL12 in breast tumors than normal mammary tissue [28].
However, while these data demonstrate that carcinoma-associated
fibroblasts are characterized by increased CXCL12, it remains unclear
to what extent total CXCL12 in breast cancers differs from normal
tissue and affects prognosis. On the basis of expression of CXCL12-α
and -β in two different breast cancer microarray data sets and
immunohistochemistry (IHC) of primary breast tumors, Mirisola and
colleagues reported that higher expression levels of CXCL12-α and -β
correlate with better disease-free survival [29]. However, a separate
high throughput analysis of CXCL12 expression concluded that
higher CXCL12 levels correlate with increased metastasis and local
recurrence in breast cancer [17]. Determining effects of high versus
low CXCL12 on prognosis and disease progression in breast cancer is
essential to direct optimal use of therapeutic antibodies and other
agents being developed for CXCL12-targeted cancer therapy [30].
Prior genetic analyses of mRNA for CXCL12 isoforms have used
microarrays, which frequently lack probes to detect specific isoforms
of these genes. However, next-generation sequencing overcomes this
limitation. Using bioinformatics analysis of publicly available data sets
from The Cancer Genome Atlas (TCGA), we investigated expression
of CXCL12 isoforms, as well as CXCR4 and CXCR7 in breast cancer.
We then correlated patterns of expression with important molecular
phenotypes, clinical parameters, and outcomes in these patients.These analyses revealed distinct differences in expression for various
isoforms of these genes. We show that low levels of expression of
CXCL12 correlate with worse prognosis in breast cancer with
isoform-specific differences among α, β, γ, and δ isoforms. These
data demonstrate the impact of CXCL12 isoforms in breast cancer
and underscore the need to better understand functional differences
among these molecules in disease progression and therapy.
Methods
Study Design and RNA Sequencing
Publicly available RNA next-generation sequencing and clinical
data (844 breast cancer and 104 benign breast samples) were retrieved
from TCGA for breast cancer [31]. Additional clinical data such as
PAM50 clustering and clinical follow-up for the TCGA were
obtained from the UCSC Cancer Genomics Browser [32]. RNA
sequencing data for seven breast cancer cell lines (two samples each)
were obtained from the Illumina iDEA database (www.illumina.
com). Three of these cell lines have been shown to have metastatic
potential (BT20, MDA-MB-231, and MDA-MB-468), and four cell
lines have been shown to have no metastatic potential (BT474,
MCF7, T47D, and ZR-75-1) [33–35]. RNA sequencing reads were
aligned to the genome with Tophat [36] using Genome Reference
Consortium Human Build 37 (GRCh37 or hg19) (www.ncbi.nlm.
nih.gov) as the reference genome.
Seven hundred eighty-five of the cancer samples had clinical data
from TCGA, and 832 had data from UCSC Cancer Genome
Browser. Her2 status was not included as a column, so we calculated
it based on the IHC data column. For cases with equivocal IHC, we
then used the in situ hybridization data column.
Normalization was performed using Fragments per Kilobase per
Million, and isoform expression values were generated using Cufflinks
with Ensembl version 69 as the reference transcriptome [37].
Cufflinks calculates isoform expression levels using a statistical model
in which the probability of observing a given fragment is a linear
function of the transcript abundance. Gene level expression is the sum
of transcript level expression, as each read is assigned to a single
transcript. Tophat was chosen because it is the standard sequence
aligner used by Cufflinks [38].
Statistical and Bioinformatics Analysis
Correlation coefficients were generated using Spearman's correla-
tion. Hierarchical clustering was performed on the covariance
matrices to generate heat maps. Expression levels of the isoforms
and at the gene level were compared across clinical and pathologic
groups such as cancer versus normal, tumor stage, histology,
hormone receptor status, and PAM50 cluster [39]. Means between
groups were compared using analysis of variance. Expression was
divided into high versus low expression using the median expression
value. Kaplan-Meier curves were generated for the high and low
expression groups and compared using the log-rank test for
metastasis-free survival (MFS), recurrence-free survival (RFS), and
overall survival (OS). Hazard ratios (HRs) were generated using
univariate Cox regression. Multi-gene analysis was performed using
Cox regression with expression of each gene/isoform as a covariate.
Comparison of expression between metastatic versus non-metastatic
cell lines was performed using Student's t-test. Statistics and plots
were generated using the R statistical computing software and
GraphPad Prism.
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Differential Expression of CXCL12 Isoforms, CXCR4, and
CXCR7 in Breast Cancer versus Normal Breast Tissue
Studies of isoforms of CXCL12 in cancer and other diseases have
been limited by the lack of isoform-specific probes on microarrays and
antibodies for IHC. As a result, studies have focused predominantly
on only the α and β isoforms of CXCL12. To overcome limitations of
microarrays and antibodies, we investigated expression levels of all
isoforms of CXCL12 and receptors CXCR4 and CXCR7 in breast
cancer using the TCGA RNA sequencing data set. The clinical and
pathologic characteristics of the tumor samples and patients in this
data set are shown in Table 1.
The Cufflinks analysis program assigns each read to individual
isoforms such that the sum of expression levels for a specific isoform is
equal to the gene level of expression. On the basis of this analysis, we
determined that the most common isoform of CXCL12 in breast
cancer is α (65%), followed by β (27%) N γ (5%) N δ (2%). We
detected only very low levels of expression for CXCL12-ε (0.1%)
and -φ (0.2%) and therefore refrained from statistical inference using
these isoforms.
To establish for the first time correlations among CXCL12 isoforms,
CXCR4, and CXCR7, we examined the Spearman's covariance matrix
with hierarchal clustering for breast cancer and normal tissues,
respectively (Figure 1, A and B). In breast cancer, CXCL12-α and -β
were highly correlated (correlation coefficient of 0.91), and these two
isoforms also correlated highly with gene-level expression of CXCL12
(correlation coefficients of 0.99 and 0.95 for CXCL12-α and -β,
respectively; Figure 1A). By comparison, the γ, ε, and φ isoforms of
CXCL12 correlated moderately with gene-level expression of α and β
(correlation coefficients of 0.44 to 0.59). Interestingly, the δ isoform,
which is not well characterized in the literature, correlated very poorlyTable 1. Cancer Patient Characteristics Compiled from TCGA.
Mean Age (Years) 58.0 ± 13.3 Median Follow-Up (Months) 23.7
Variable (n) Variable (n)
ER Node stage
Positive 579 0 361
Negative 170 1+ 409
PR Death
Positive 505 Positive 104
Negative 241 Negative 675
Her2 receptor Recurrence
Positive 141 Positive 53
Negative 508 Negative 315
PAM50 status Metastasis
Basal 138 Positive 48
Her2 66 Negative 324
Luminal A 414 Gender
Luminal B 190 Female 776
Normal 24 Male 9
Overall stage Menopause
1 127 Pre-menopause 181
2 127 Post-menopause 493
3 171 Race
4 15 White 591
Tumor stage Black or African American 55
1 207 Asian 51
2 467 American Indian or Alaskan Native 1
3 76
4 32with the other CXCL12 isoforms (correlation coefficients of −0.11
to 0.27) and in cancer samples, clustered with CXCR4 and CXCR7
rather than with the other CXCL12 isoforms. CXCR4 and CXCR7
displayed a weak positive correlation with gene-level expression of
CXCL12 and its α and β isoforms but did not correlate with each other.
These same general correlations were present in normal samples
(Figure 1B). However, in normal samples, CXCR7 tended to correlate
inversely with CXCR4, and CXCR7 also exhibited modest to strong
correlations withCXCL12-α and -β and overall gene-level expression of
this chemokine.
We next investigated levels of expression for various chemokine and
receptor isoforms in cancer and normal tissues. While previous
publications report discordant results for CXCL12 in breast cancer
versus normal breast, our analysis showed significant down-regulation of
CXCL12-α, -β, and -γ in cancer (Figure 1C). Expression of CXCL12-δ
also decreased in cancer as compared with normal, although differences
were not significant. Similarly, CXCR7 was downregulated in cancer.
CXCR4 demonstrated the opposite pattern with up-regulation in
cancer, consistent with prior literature [15,17,18].
Variations among CXCL12 Isoforms, CXCR4, and CXCR7
with Clinical and Molecular Staging Parameters
Within cancer samples, CXCL12-α, -β, and -γ varied significantly
with tumor stage (Figure 2A). For these isoforms of CXCL12, lower
stage tumors had higher levels of expression with the highest
amounts of each isoform present in stage I primary breast tumors.
We observed a similar trend for gene-level expression of CXCL12.
We also compared differences in expression of various isoforms with
histologic classifications of breast cancer. Invasive ductal and
invasive lobular carcinomas comprise the majority of the TCGA
data set, and most of the mixed histology samples contain features of
both invasive ductal and lobular cancer. Gene-level expression of
CXCL12, as well as α, β, and γ isoforms, showed significant
variations across different histologic groups (Figure 2B). Amounts of
total CXCL12 and these three isoforms were highest in invasive
lobular cancer with a rank order of invasive lobular N mixed N inva-
sive ductal carcinoma. We note that lowest levels of expression for
CXCL12 and the α, β, and γ isoforms occurred in less common
histologic types of breast cancer, medullary and mucinous. Other
isoforms of CXCL12 did not vary significantly with tumor stage or
histologic type, and we also did not identify significant correlations
with gene-level CXCR4 or CXCR7.
In clinical oncology, breast cancers are categorized on the basis of
hormone receptors [estrogen (ER) and progesterone (PR)] and
amplification of the oncogene Her2. These categories determine
prognosis and treatment options [40]. We analyzed expression of
CXCL12, CXCR4, and CXCR7 and individual isoforms in tumors
positive for both ER and PR, Her2 only, and all three receptors (triple
positive), as well as primary cancers lacking expression of these three
receptors (triple negative). Gene-level expression of CXCL12 and the
α and β isoforms each varied significantly across these subtypes with
highest amounts in ER/PR positive and triple positive cancers
(Figure 3A). By comparison, levels of overall CXCL12, CXCL12-α,
and CXCL12-β decreased in triple negative cancer and to an even
greater extent in Her2 positive tumors. Other isoforms of CXCL12
did not vary significantly with receptor status. CXCR7 varied with
receptor status in a pattern comparable to CXCL12 (Figure 3A).
Levels of CXCR7 were highest in ER/PR positive and triple positive
tumors with lower expression in triple negative and Her2 positive
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Figure 1. Spearman's covariance matrix with hierarchal clustering of CXCL12 isoforms, CXCR4, and CXCR7 for (A) breast cancer and
(B) normal tissues. (C) Expression levels of CXCL12 isoforms, CXCR4, and CXCR7 in breast cancer and normal tissues. Expression levels
are means ± SEM. *P b .05 and **P b .001.
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CXCR4, which was elevated in triple negative breast cancer relative to
the other groups [41].
More recently, breast cancers have been classified into
intrinsic molecular subtypes (Normal-like, Luminal A, Luminal
B, Her2-enriched, and Basal-like) defined by a 50-gene panel
referred to as PAM50. Intrinsic subtypes add prognostic and
predictive information to standard metrics used to categorize breast
cancer. When analyzed across intrinsic subtypes, CXCL12 and its
α, β, and γ isoforms varied significantly (Figure 3B). Expression
was highest in the Normal-like cluster, which is consistent with
our data in Figure 1A showing up-regulation of these isoforms in
normal samples. Luminal A had the next highest expression with
Luminal B, Her2-enriched, and Basal clusters exhibiting lower
expression. We also identified significant variations of
receptors with intrinsic subtypes of breast cancer. CXCR4 showed
differential expression among clusters with lowest levels in Luminal
A and Luminal B subtypes and highest expression in Basal cancers.
By comparison, levels of CXCR7 were highest in Luminal A and
Luminal B subtypes.CXCL12 and its α, β, and γ isoforms vary significantly with
race. We identified higher expression in whites than Asians or
African-Americans (Figure W1A). Gene-level CXCL12 and the
α isoform also changed significantly by age group with levels peaking
in the 50 to 60 year age group relative to younger or older patients
(Figure W1B). CXCL12-β and -γ showed a similar pattern across age
groups, although differences were not significant. We did not identify
significant correlations for race or age groups for CXCR4 or
CXCR7. CXCL12 and its α, β, and γ isoforms vary significantly
with race. We identified higher expression in whites than Asians or
African-Americans (Figure W1A). Gene-level CXCL12 and the α
isoform also changed significantly by age group with levels peaking in
the 50 to 60 year age group relative to younger or older patients
(Figure W1B). CXCL12-β and -γ showed a similar pattern across age
groups, although differences were not significant. We did not identify
significant correlations for race or age groups for CXCR4 or CXCR7.
CXCL12 isoforms correlate with patient outcomes
We next examined the correlation of gene and isoform expression
with important clinical outcomes in breast cancer: metastasis,
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expression of gene-level CXCL12 demonstrated that low-expression
corresponded with a significantly worse MFS (P b .008, HR = 2.2)
but not RFS or OS (Figure 4, A–C). Similarly, low expression of
CXCL12-α corresponded with significantly worse MFS (P b .033,
HR = 1.9) but not RFS or OS (Figure 4, D–F). Unlike CXCL12-α,
low levels of both CXCL12-β and -γ correlated with significantly
worse MFS (β isoform P b .0015, HR = 2.6; γ isoform P b .011,
HR = 2.2) and RFS (β isoform P b .028, HR = 2.1; γ isoform
P b .024, HR = 2.1) but not OS (Figure 4, G–L).
CXCL12-δ, the isoform that does not correlate with expression
patterns of other isoforms in breast cancer or normal breast tissue, had
a different association with outcomes. Low expression of the δ
isoform also showed trends for reduced MFS and RFS (Figure 4, M
and N), although not statistically significant (MFS, P b .16, HR =
1.5; RFS, P b .077, HR = 1.7). Notably, low CXCL12-δ was the
only CXCL12 isoform correlated with worse OS (P b .0035, HR =
1.8; Figure 4O).
CXCL12, CXCR4, and CXCR7 do not operate independently but
as important components in a complex network. We examined the
expression levels of CXCL12-δ, the least understood isoform in the
context of the expression of the other genes in the pathway. Low
CXCL12-δ is independently prognostic for OS even after taking
into account CXCL12, CXCR4, and CXCR7 expression (P b .004,
HR = 0.56) and shows the same trend in MFS and RFS (Figure 5,
A–C) multi-gene analyses.
CXCL12 Isoforms Correlate with Metastatic Potential in
Breast Cancer Cell Lines
By nature, clinical samples such as the TCGA contain a mix of cell
types, including tumor cells, normal breast tissue, and vasculature,
making it difficult to identify the cell type(s) producing each transcript.To overcome this limitation, we examined RNAseq data in seven breast
cancer cell lines for CXCL12 isoforms. Surprisingly, we found that
isoform expression shows a different trend than those in the TCGA
samples, with γ showing the highest expression proportion (42%),
followed by α (33%) N β (24%). We detected only very low levels of
expression for CXCL12-δ (0.5%), -ε (0.1%) and -φ (0.2%).
We compared CXCL12 isoform expression levels between cell lines
with metastatic potential and those without metastatic potential
(Figure 6) and found that CXCL12 and its α and β isoforms were
expressed significantly lower in samples with metastatic potential,
which is in agreement with the trends of isoform expression in clinical
samples. The same trend was seen with CXCL12-γ, though not
statistically significant.
Discussion
While alternative splicing formerly appeared to be limited to a small
number of genes, studies now demonstrate that almost all human
genes undergo alternative splicing to create protein diversity [42].
Variants generated by loss of splicing fidelity or regulated transitions
between isoforms drive cancer and many other human diseases,
generating a large number of novel transcripts and proteins expressed
predominantly or uniquely in cancer. For example, up to 36 different
isoforms of the Wilms tumor gene 1 have been identified with specific
variants specifically upregulated in acute and chronic myeloid
leukemias, suggesting key functions in cancer initiation and/or
progression [43,44]. Similarly, isoforms of vascular endothelial
growth factor exhibit distinct functional activities in tumor
angiogenesis that vary on the basis of anatomic site, emphasizing
the importance of tumor environments on isoforms [45–47]. In
addition to conferring unique functions to cancer cells and tumor
environments, alternative splicing offers a rich source of potential
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Figure 4.MFS, RFS, and OS curves for CXCL12 isoforms. Higher levels of gene-level CXCL12 (A–C), CXCL12-α (D–F), -β (G–I), and -γ (J–L)
generally correlate with improved MFS and RFS. Higher expression of CXCL12-δ (M–O) correlates with better OS.
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accounting for gene-level CXCL12, CXCR4, and CXCR7. Error bars represent 95% confidence intervals.
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therapies based on alternative splicing may have a higher likelihood
for success than conventional approaches centered on a whole gene or
protein. Collectively, these studies highlight the clinical relevance of
identifying disease-associated changes in alternative splicing.
Prior research has established central functions of CXCL12 in
cancer growth and metastasis, but very few studies have investigated
isoforms of CXCL12 in cancer. In renal cell carcinoma, an analysis
limited to CXCL12-α and -β revealed that only the β isoform
correlated with tumor grade and infiltration of CD8 T cells [48].
CXCL12-β also was upregulated in bladder cancer, a disease in
which expression of this isoform predicted metastasis and disease-
specific mortality [49]. This study of bladder cancer also showed
that amounts of CXCL12-α did not change between normal and
malignant tissues, while CXCL12-γ was undetectable. Neither
these studies nor any others have investigated the other three
CXCL12 isoforms (δ, ε, or φ) in cancer due to the lack of antibodies
against these isoforms and limitations in high throughput
technology.
Next-generation sequencing allows our study to fill notable gaps in
knowledge about the CXCL12/CXCR4/CXCR7 pathway by
providing the first characterization of expression levels of all known
alternative splicing variants of CXCL12 in breast cancer or any other
malignancy. We found that primary human breast cancers expressCX
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Figure 6. Expression of gene-level CXCL12 and those of CXCL12-α
and -β isoforms are significantly higher in cell lines without
metastatic potential compared to cell lines with metastatic
potential. Expression levels are means ± SEM. *P b .05.four different isoforms of CXCL12 in rank order of α N β N γ N δ,
while ε and φ essentially were undetectable in the TCGA breast
cancer samples. Expression of CXCL12 isoforms varied significantly
across many different clinical and molecular categories of breast
cancer, including stage, histologic type, intrinsic molecular subtype,
and hormone receptor status. Changes in abundance of transcripts
typically occurred in parallel for each CXCL12 isoform as would be
expected for an mRNA regulated by the same common promoter
elements. We also discovered lower levels of CXCL12 transcripts in
subtypes of breast cancer regarded as more aggressive, such as triple
negative and Her2 amplified, and with progression to higher stage.
These findings corresponded with Kaplan-Meier analyses, where low
expression of CXCL12 and specific isoforms was associated with
worse outcomes. We identified isoform-specific effects on MFS, RFS,
and OS, with low levels of CXCL12-α, -β and -γ significantly
correlated with worse MFS and RFS. Most notably, we note that low
levels of CXCL12-δ associated with worse OS and showed the same
trend for RFS and MFS, despite the fact that CXCL12-δ expression
does not correlate with expression of the other isoforms. This
relationship is robust and persists even after taking into account
CXCL12, CXCR4, and CXCR7 expression in multi-gene analysis,
indicating the independent prognostic significance of CXCL12-δ.
These data provide the first evidence that CXCL12-δ is expressed in
human cancer and correlate with a patient outcome.
Expression levels of CXCL12 in breast cancer cell lines generally
mirror conclusions from the clinical samples that lower levels of
CXCL12 correlate with worse prognosis. We found that breast
cancer cell lines without metastatic potential (in mouse models) had
higher levels of CXCL12 expression than cell lines that metastasize
more widely. Studies of CXCL12 in breast cancer focus on secretion
of this chemokine by stromal cells in primary and metastatic sites,
frequently overlooking effects of CXCL12 produced by cancer cells.
However, epigenetic silencing of the CXCL12 promoter has been
reported in breast cancer cells with greater metastatic potential, and
re-expressing CXCL12 limits metastatic disease in mouse xenograft
models [25]. Our analysis of cell lines may inform likely sources of
various CXCL12 isoforms in tumor microenvironments. Breast
cancer cells express CXCL12-α, -β, and -γ with very minimal
expression of δ, which could indicate that stromal cells are the
predominant source of the δ isoform in primary breast cancers. We
also note that CXCL12-γ is higher than α and β in our panel of
breast cancer cell lines, which is opposite the pattern in primary
tumors. Differences between data from cell lines versus tumors may
reflect dynamic regulation of CXCL12 isoforms in vivo, greater
436 A Comprehensive Analysis of CXCL12 Isoforms Zhao et al. Translational Oncology Vol. 7, No. 3, 2014contributions of stromal cells to overall expression of CXCL12-α
and -β in breast tumors, or simply genomic changes as the original
cancer samples were transformed into immortalized cell lines. In
addition, CXCL12 levels within the tumor microenvironment may
be affected by posttranslational modification, such as cleavage by
CD26 or matrix-metalloproteinase-2 [50,51].
Isoform-specific differences in expression and breast cancer
outcomes suggest distinct functions of individual splice variants of
CXCL12 on disease progression. Recent studies have begun to
identify unique biochemical properties of CXCL12 isoforms,
particularly α, β, and γ. While all isoforms share the same core
structure, CXCL12-β, -γ, -δ, -ε, and -φ differ by inclusion of exons
that add 4, 40, 51, 1, or 11 additional amino acids, respectively, to
the carboxy terminus of the molecule [24]. Particularly for
CXCL12-γ, the added carboxy-terminal amino acids are enriched
with basic residues that enhance binding to heparan sulfates and
other negatively charged extracellular matrix molecules [52]. By
comparison, CXCL12-β and, to a greater extent, -γ have reduced
binding affinities for receptors CXCR4 and CXCR7. Biochemical
differences in binding to receptors and extracellular matrix
molecules translate to different functional outcomes. In mouse
models, CXCL12-γ promotes chemotaxis of immune cells and
endothelial progenitors to a significantly greater extent than other
isoforms [53,54]. Greater binding to heparan sulfates and
extracellular matrix molecules also limits proteolytic degradation
of CXCL12 [55]. These studies highlight functional differences
among CXCL12 isoforms in receptor binding, chemotaxis, and
stability that could alter outcomes in breast cancer. Our data also
support further studies analyzing functional differences among
CXCL12 isoforms, especially for CXCL12-δ.
Correlation between gene transcript data and protein expression is
dependent on the gene and tissue type. However, mRNA expression
is generally a good proxy for protein expression and is frequently used
as biomarkers.[56–58] Gene expression also forms the basis of the
PAM50 molecular subtyping of breast cancer as well as Oncotype Dx,
a widely used predictive model for chemotherapy response in breast
cancer.[59–62] Specifically for CXCL12-α, -β, and -γ, mRNA levels
as measured by quantitative reverse transcription–polymerase chain
reaction correlate with protein levels as measured by ELISA.[63] We
also recognize that this study has limitations based on the data
publicly available through the TCGA. While the data set contains
transcript data for a large number of patients, the median follow-up
time is relatively short, and therefore, the number of metastasis and
recurrence events is small, thus limiting our statistical power. This
likely accounts for why the P values for CXCL12-δMFS and RFS do
not reach significance. We also do not know the full treatment history
for all patients, such as exact chemotherapy and radiation regimens,
and there is likely significant heterogeneity in treatments given the
multi-institutional nature of the data. Even with these limitations, we
were able to identify significant differences in outcomes for isoforms
of CXCL12.
In summary, our data reveal new associations of CXCL12, CXCR4,
and CXCR7 gene expression with molecular, histologic, and clinical
categories of human breast cancer. In addition, we have identified
isoform-specific differences in CXCL12 for outcomes in breast
cancer, suggesting distinct biochemical functions of isoforms in
disease progression. These compelling results establish the foundation
for mechanistic preclinical studies of these isoforms in breast cancer.
Additional studies are also warranted to elucidate the biologic andfunctional differences between the CXCL12 isoforms and validate
them as potential biomarkers.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.tranon.2014.04.001.References
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